Credit Suisse Ag Zynerba Pharmaceuticals, Inc. Transaction History

Credit Suisse Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$3.72 - $5.35 $75,486 - $108,562	-20,292 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$3.83 - $5.98 $77,718 - $121,346	20,292 New	20,292 $107,000
Q4 2020 Feb 12, 2021	SELL	$3.27 - $4.64 $48,615 - $68,982	-14,867 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$3.23 - $4.3 $48,020 - $63,928	14,867 New	14,867 $49,000
Q4 2017 Feb 14, 2018	SELL	$8.69 - $14.59 $99,700 - $167,391	-11,473 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.73 - $9.44 $65,740 - $108,305	11,473	11,473 $96,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.